Review Article
Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis
Table 1
Major features of eleven references included in this meta-analysis.
| | Author year | County | Study period | Study design | Sample size | Age (years) | Sex (M/F) | Staging criteria |
| | He (2017) | China | 2007-2013 | Retrospective | 241 | 50.3 | 210 (87%)/31 (13%) | Milan criteria | | Liu (2020) | China | 2011-2016 | Retrospective | 206 | 53 | 160 (78%)/46 (22%) | AJCC 8th | | Jin (2015) | China | 1997-2008 | Retrospective | 371 | NA | 323 (87%)/48 (13%) | NA | | Yang (2015) | China | 2009-2015 | Retrospective | 189 | 53.4 | 161 (85%)/28 (15%) | BCLC | | Zhao (2019) | China | 2009-2013 | Retrospective | 429 | 54 | 392 (91%)/37 (9%) | AJCC 7th | | Zheng (2019) | China | 2011-2013 | Retrospective | 78 | 60.12 | 67 (86%)/11 (14%) | BCLC | | Suo (2019) | China | 1993-2010 | Retrospective | 463 | 50.14 | 401 (87%)/62 (13%) | BCLC | | Qin (2019) | China | 2013-2017 | Retrospective | 191 | 48.62 | 154 (81%)/37 (19%) | AJCC 8th | | Chen (2020) | China | 2007-2016 | Retrospective | 983 | 50.5 | 829 (84%)/154 (16%) | BCLC | | Liao (2021) | China | 2009-2016 | Retrospective | 416 | 50.47 | 359 (86%)/57 (14%) | NA | | Wu (2021) | China | 2014-2017 | Retrospective | 347 | NA | 290 (83.6%)/57 (16.4%) | BCLC/AJCC8th | | Author year | Tumor stage | Treatment | Cut-off value | Cut-off selection | Follow-up months | Survival analysis | NOS score | | He (2017) | Size <3; 3-5 cm | Surgical resection | 32 | Mean value | 54.2 | OS, PFS | 7 | | Liu (2020) | I-IV | Surgical resection | 18.734 | ROC analysis | 35 | OS | 8 | | Jin (2015) | I-IV | Surgical resection | 25.2 | ROC analysis | 20 | OS, PFS | 7 | | Yang (2015) | A-C | TACE | 57 | R software | 30.2 | OS | 8 | | Zhao (2019) | I-IV | Palliative treatments | 86.3 | ROC analysis | NA | OS | 8 | | Zheng (2019) | B-C | TACE | 22.82 | ROC analysis | 18.16 | OS, PFS | 8 | | Suo (2019) | 0-C | Surgical resection | 25.2 | ROC analysis | 47.12 | OS, PFS | 8 | | Qin (2019) | I-III | Surgical resection | 26.06 | ROC analysis | 32.4 | OS | 8 | | Chen (2020) | A | Surgical resection | 26.6 | X-tile | 48.8 | OS, PFS | 8 | | Liao (2021) | I-III | Surgical resection | 22.6 | ROC analysis | 36.7 | O, PFS | 8 | | Wu (2021) | Size≤5; >5 cm | Surgical resection | 31 | ROC analysis | 45 | OS, PFS | 8 |
|
|
